Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Etrolizumab (Primary) ; Adalimumab
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms HIBISUS II
- Sponsors Roche
- 04 Nov 2019 Planned End Date changed from 29 Dec 2020 to 1 Jul 2020.
- 04 Nov 2019 Planned primary completion date changed from 6 Oct 2020 to 11 Mar 2020.
- 19 Jul 2019 Planned primary completion date changed from 29 Dec 2020 to 6 Oct 2020.